Scarica l'app Stockscreener
9.13
6.78%
0.58
Precedente Chiudi:
$8.55
Aprire:
$8.58
Volume 24 ore:
39,060
Relative Volume:
0.09
Capitalizzazione di mercato:
$228.39M
Reddito:
-
Utile/perdita netta:
$-102.09M
Rapporto P/E:
-8.6952
EPS:
-1.05
Flusso di cassa netto:
$-108.72M
1 W Prestazione:
+9.34%
1M Prestazione:
-2.77%
6M Prestazione:
+149.45%
1 anno Prestazione:
+61.02%
Intervallo 1D:
$8.50
$9.18
Intervallo di 1 settimana:
$7.5262
$9.18
Portata 52W:
$2.2045
$12.78
Dbv Technologies Adr Stock (DBVT) Company Profile
Nome
Dbv Technologies Adr
Settore
Industria
Telefono
33(0)155427878
Indirizzo
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Confronta DBVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
9.13 | 228.39M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-29 | Ripresa | Goldman | Sell |
| 2023-01-04 | Aggiornamento | Societe Generale | Hold → Buy |
| 2022-12-16 | Downgrade | Goldman | Neutral → Sell |
| 2022-05-10 | Downgrade | Goldman | Buy → Neutral |
| 2021-09-14 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-01-22 | Downgrade | Societe Generale | Hold → Sell |
| 2020-11-02 | Aggiornamento | Societe Generale | Sell → Hold |
| 2020-08-06 | Downgrade | Societe Generale | Buy → Sell |
| 2020-08-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-17 | Downgrade | Stifel | Buy → Hold |
| 2020-01-09 | Aggiornamento | Stifel | Hold → Buy |
| 2019-12-16 | Iniziato | Citigroup | Buy |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Iniziato | Goldman | Buy |
| 2018-12-20 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Downgrade | Jefferies | Buy → Hold |
| 2018-12-20 | Downgrade | Stifel | Buy → Hold |
| 2017-10-31 | Aggiornamento | Societe Generale | Sell → Hold |
| 2017-10-24 | Downgrade | Societe Generale | Buy → Sell |
| 2017-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Iniziato | Deutsche Bank | Buy |
| 2017-03-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2016-09-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-03 | Iniziato | Barclays | Overweight |
| 2015-10-23 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Dbv Technologies Adr Borsa (DBVT) Ultime notizie
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document - GlobeNewswire
DBV Technologies Reveals Special CEO Pay Package Ahead of Critical Shareholder Vote - Stock Titan
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
DBV Technologies (NASDAQ:DBVT) Raised to Sell at The Goldman Sachs Group - Defense World
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 By Investing.com - Investing.com South Africa
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target By Investing.com - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target - Investing.com
DBV Technologies (NASDAQ:DBVT) Price Target Raised to $21.00 at JMP Securities - Defense World
European ADRs Rise On S&P Europe Select Index - Finimize
DBV Technologies’ SWOT analysis: peanut allergy treatment stock faces pivotal trial - Investing.com
European ADRs Slip As US Index Notes Mixed Gains And Losses - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice - Nasdaq
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
Combined General Meeting of June 11, 2025 - GlobeNewswire
DBV Technologies Sets Critical Shareholder Meeting: Key Documents Now Available - Stock Titan
European ADRs Show Modest Gains With Standout Performers - Finimize
StockNews.com Upgrades DBV Technologies (NASDAQ:DBVT) to “Hold” - Defense World
FY2025 EPS Forecast for DBV Technologies Boosted by Analyst - Defense World
European ADRs Dip With Mixed Performances Across Key Sectors - Finimize
What is HC Wainwright’s Estimate for DBVT Q2 Earnings? - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A.DBVT - Barchart.com
HC Wainwright Issues Positive Forecast for DBV Technologies (NASDAQ:DBVT) Stock Price - Defense World
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - The Manila Times
DBV Technologies stock target raised to $16 by H.C. Wainwright - Investing.com Nigeria
JMP Securities Boosts DBV Technologies (NASDAQ:DBVT) Price Target to $15.00 - Defense World
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World
DBV Technologies Reports First Quarter 2025 Financial Results - EIN News
DBV Technologies Secures Massive $306.9M Financing Despite Q1 Losses: Cash Runway Extended - Stock Titan
European ADRs Show Gains Despite Mixed Performances In Key Sectors - Finimize
Dbv Technologies Adr Azioni (DBVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dbv Technologies Adr Azioni (DBVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '24 |
Sale |
0.98 |
1,785 |
1,749 |
79,367 |
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):